Delving into the Latest Updates on 益福生医股份有限公司 with Synapse

概览

疾病领域	数量

神经系统疾病	3
免疫系统疾病	2
内分泌与代谢疾病	1

排名前五的药物类型	数量

益生菌	6

排名前五的靶点	数量

Cholesterol x Lipid	1

关联

6

项与益福生医股份有限公司相关的药物

PS-128

靶点-

作用机制

细菌替代物 [+1]

在研机构

益福生医股份有限公司初创企业

原研机构

益福生医股份有限公司初创企业

在研适应症

神经系统疾病

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

加拿大

首次获批日期2022-04-07

PS-23

靶点-

作用机制

胃肠道微生物调节剂

在研机构

国立台湾大学 [+1]

原研机构

益福生医股份有限公司初创企业

在研适应症

焦虑症 [+5]

非在研适应症-

最高研发阶段临床阶段不明

首次获批国家/地区-

首次获批日期-

A-17

靶点-

作用机制

免疫调节剂

在研机构

益福生医股份有限公司初创企业

原研机构

益福生医股份有限公司初创企业

在研适应症

过敏

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

13

项与益福生医股份有限公司相关的临床试验

NCT06486064 / RecruitingN/AIIT

Evaluating the Potential of Probiotic Supplementation Sleep Quality

This study aims to evaluate the feasibility of probiotics in improving sleep indicators through clinical human studies. Previous animal experiments have confirmed that Limosilactob acillus fermentum PS150 and heat-treated Lactobacillus fermentum HT-PS150 strains have the effect of improving sleep. 90 subjects will be recruited, 45 in each group. They will be given either HT-PS150 or placebo for 8 weeks and their blood, urine, saliva and questionnaire will be evaluated.

开始日期2024-07-30

申办/合作机构

益福生医股份有限公司初创企业

NCT06381479 / CompletedN/AIIT

Exploring the Effects of Probiotics on Workplace Related Stress Symptoms

There is still a lack of research to explore the interaction between high-pressure workers and probiotics to improve the intestinal microbiota, sleep, inflammation and anti-oxidation. A total of 120 subjects are expected to be recruited and divided into two groups of 60 subjects, receiving probiotics or placebo, and completing a 8-week trial period.

开始日期2024-04-19

申办/合作机构

益福生医股份有限公司初创企业

NCT06361368 / RecruitingN/AIIT

Efficacy Assessment of Probiotics in Improving Sleep Indices

To determine whether PS150 (1) reduces insomnia symptoms, (2) improves sleep quality, (3) adjusts autonomic nervous system functioning, (4) reduces the severity of anxiety and depressive symptoms, and (5) adjusts microbiome and endocrine functions.

开始日期2024-04-11

申办/合作机构

国立阳明大学

[+1]

100 项与益福生医股份有限公司相关的临床结果

登录后查看更多信息

0 项与益福生医股份有限公司相关的专利（医药）

登录后查看更多信息

23

项与益福生医股份有限公司相关的文献（医药）

2024-08-09·International journal of molecular sciences

The Beneficial Effects of Lacticaseibacillus paracasei subsp. paracasei DSM 27449 in a Letrozole-Induced Polycystic Ovary Syndrome Rat Model.

Article

作者: Cheng, Shih-Hsuan ; Lin, Yu-Fen ; Wu, Chien-Chen ; Lee, Yan Zhang ; Tsai, Ying-Chieh

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting women of reproductive age globally. Emerging evidence suggests that the dysregulation of microRNAs (miRNAs) and gut dysbiosis are linked to the development of PCOS. In this study, the effects of Lacticaseibacillus paracasei subsp. paracasei DSM 27449 (DSM 27449) were investigated in a rat model of PCOS induced by letrozole. The administration of DSM 27449 resulted in improved ovarian function, reduced cystic follicles, and lower serum testosterone levels. Alterations in miRNA expressions and increased levels of the pro-apoptotic protein Bax in ovarian tissues were observed in PCOS-like rats. Notably, the administration of DSM 27449 restored the expression of miRNAs, including miR-30a-5p, miR-93-5p, and miR-223-3p, leading to enhanced ovarian function through the downregulation of Bax expressions in ovarian tissues. Additionally, 16S rRNA sequencing showed changes in the gut microbiome composition after letrozole induction. The strong correlation between specific bacterial genera and PCOS-related parameters suggested that the modulation of the gut microbiome by DSM 27449 was associated with the improvement of PCOS symptoms. These findings demonstrate the beneficial effects of DSM 27449 in ameliorating PCOS symptoms in letrozole-induced PCOS-like rats, suggesting that DSM 27449 may serve as a beneficial dietary supplement with the therapeutic potential for alleviating PCOS.

2023-04-05·International journal of molecular sciences

Neuroprotective Effects of Lactobacillus plantarum PS128 in a Mouse Model of Parkinson's Disease: The Role of Gut Microbiota and MicroRNAs.

Article

作者: Tsai, Ying-Chieh ; Chang, Min-Yu ; Cheng, Shih-Hsuan ; Wu, Chien-Chen ; Lin, Yu-Fen ; Lee, Yan Zhang

Parkinson's disease (PD) is a neurodegenerative disease characterized by motor deficits and marked neuroinflammation in various brain regions. The pathophysiology of PD is complex and mounting evidence has suggested an association with the dysregulation of microRNAs (miRNAs) and gut dysbiosis. Using a rotenone-induced PD mouse model, we observed that administration of Lactobacillus plantarum PS128 (PS128) significantly improved motor deficits in PD-like mice, accompanied by an increased level of dopamine, reduced dopaminergic neuron loss, reduced microglial activation, reduced levels of inflammatory factors, and enhanced expression of neurotrophic factor in the brain. Notably, the inflammation-related expression of miR-155-5p was significantly upregulated in the proximal colon, midbrain, and striatum of PD-like mice. PS128 reduced the level of miR-155-5p, whereas it increased the expression of suppressor of cytokine signaling 1 (SOCS1), a direct target of miR-155-5p and a critical inhibitor of the inflammatory response in the brain. Alteration of the fecal microbiota in PD-like mice was partially restored by PS128 administration. Among them, Bifidobacterium, Ruminiclostridium_6, Bacteroides, and Alistipes were statistically correlated with the improvement of rotenone-induced motor deficits and the expression of miR-155-5p and SOCS1. Our findings suggested that PS128 ameliorates motor deficits and exerts neuroprotective effects by regulating the gut microbiota and miR-155-5p/SOCS1 pathway in rotenone-induced PD-like mice.

2023-01-01·Frontiers in microbiology

Exopolysaccharide is the potential effector of Lactobacillus fermentum PS150, a hypnotic psychobiotic strain.

Article

作者: Huang, Chin-Lin ; Tsai, Ying-Chieh ; Wen, Pei-Jun ; Deng, Fu-Sheng ; Chu, Hsu-Feng ; Chen, Ying-Tsong ; Chien, Shao-Ping ; Chao, Chi-Hsein ; Wu, Chien-Chen ; Lu, Mei-Kuang

Psychobiotics are a class of probiotics that confer beneficial effects on the mental health of the host. We have previously reported hypnotic effects of a psychobiotic strain, Lactobacillus fermentum PS150 (PS150), which significantly shortens sleep latency in experimental mice, and effectively ameliorate sleep disturbances caused by either caffeine consumption or a novel environment. In the present study, we discovered a L. fermentum strain, GR1009, isolated from the same source of PS150, and found that GR1009 is phenotypically distinct but genetically similar to PS150. Compared with PS150, GR1009 have no significant hypnotic effects in the pentobarbital-induced sleep test in mice. In addition, we found that heat-killed PS150 exhibited hypnotic effects and altered the gut microbiota in a manner similar to live bacteria, suggesting that a heat-stable effector, such as exopolysaccharide (EPS), could be responsible for these effects. Our comparative genomics analysis also revealed distinct genetic characteristics in EPS biosynthesis between GR1009 and PS150. Furthermore, scanning electron microscopy imaging showed a sheet-like EPS structure in PS150, while GR1009 displayed no apparent EPS structure. Using the phenol-sulfate assay, we found that the sugar content value of the crude extract containing EPS (C-EPS) from PS150 was approximately five times higher than that of GR1009, indicating that GR1009 has a lower EPS production activity than PS150. Through the pentobarbital-induced sleep test, we confirmed the hypnotic effects of the C-EPS isolated from PS150, as evidenced by a significant reduction in sleep latency and recovery time following oral administration in mice. In summary, we utilized a comparative approach to delineate differences between PS150 and GR1009 and proposed that EPS may serve as a key factor that mediates the observed hypnotic effect.

100 项与益福生医股份有限公司相关的药物交易

登录后查看更多信息

100 项与益福生医股份有限公司相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月18日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

4

1

批准上市

其他

1

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

PS-128	神经系统疾病更多	批准上市
PS-23	焦虑症更多	临床阶段不明
PS-150	睡眠异常更多	临床前
K-21 ( Cholesterol x Lipid )	肥胖更多	临床前
A-17	过敏更多	临床前